Drug Trial Radar · NCT04322617
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
Last checked: Nov 19, 2026Latest source record: Jun 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,200
Planned (sponsor's estimate)
Start
Mar 24, 2020
Primary completion
Mar 24, 2028
Study completion Mar 24, 2029
Sponsor
- Lead sponsor
- Hunan Province Tumor HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 26, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.
Conditions
- Non-small Cell Lung Cancer
Interventions
Anlotinib plus the same Immune Checkpoint Inhibitors.Drug
Anlotinib, 8mg po qd, D1-D14 every 21days.
Anlotinib plus the new Immune Checkpoint Inhibitors.Drug
Anlotinib, 8mg po qd, D1-D14 every 21days.
AnlotinibDrug
Anlotinib, 8mg po qd, D1-D14 every 21days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival time (PFS)Time frame: Time from first subject dose to study completion, or up to 36 month.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yongchang Zhang
Changsha, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.